Replies to post #9164 on GTC Biotherapeutics (fka GTCB)

[biopearl]

Dew, This is quite good news don't you think? Despite the blood in the streets so to speak we have a study which CONTINUES after initial enrollment in an open label fashion. The take away is #1. Not enough side effects to stop the study #2. Enough efficacy that patients are willing to continue in the open label arm. #3. Continued demand for product from our goats. I therefore think we will hear more about Merrimack and they will continue to provide at least some income to GTCB from purchase of MM-093. Flo, you have some contacts at Merrimack, do you think this is reasonable? I think I am ready to buy more but will wait for comments from others. Regards, bp